128 results on '"Suchorska, B"'
Search Results
2. Stereotactic brachytherapy using iodine 125 seeds for the treatment of primary and recurrent anaplastic glioma WHO° III
3. P11.51.B Initial temozolomide monotherapy without radiotherapy might be of limited benefit in the treatment of astrocytoma, IDH-mutant, CNS WHO grade 2 and 3
4. Questionable long-term benefit of initial temozolomide monotherapy in IDH-mutant astrocytomas grade 2 and 3
5. Optimized surgical treatment for normal pressure hydrocephalus: comparison between gravitational and differential pressure valves
6. P04.22 Tumor treating fields in high-grade glioma patients: A retrospective single-center study
7. Correction to: Biological tumour volumes of gliomas in early and standard 20–40 min 18F-FET PET images differ according to IDH mutation status
8. Radiotherapy with and without temozolomide in elderly patients with glioblastoma
9. Brain invasion is an independent risk factor for preoperative seizures in meningioma WHO grade I and II patients
10. Extrahierung von Histogramm- und Textureigenschaften aus parametrischen F-18-FET PET Bildern zur molekulargenetischen und histologischen Klassifizierung von Gliomen
11. 18 F-FET PET uptake characteristics of long-term IDH-wildtype glioma survivors
12. Influence of individual CpG methylation status on outcome in adult patients with glioblastoma multiforme receiving alkylating agent treatment
13. P14.02 Influence of individual CpG methylation status on outcome in adult patients with glioblastoma multiforme receiving alkylating agent treatment
14. Molekular-genetische und histologische Unterscheidung von Gliomen anhand charakteristischer 18F-FET PET Pharmakokinetik
15. Prognostic value of dynamic 18F-FET PET in oligodendrogliomas
16. 18F-FET PET uptake characteristics of IDH-wildtype, WHO grade II glioma
17. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial
18. P01.131 Non-invasive detection ofIDH-wildtype genotype in gliomas using dynamic18F-FET-PET
19. P05.92 Brain invasion in meningiomas previously classified as WHO grade I has limited impact on outcome
20. Prognostic value of contrast enhancement and histopathological grading in diffuse gliomas depends on IDH1/2 mutation
21. Dynamic 18F-FET PET is a powerful imaging derived biomarker in suspected low-grade gliomas independent from the influence of molecular profiling
22. K27M midline gliomas display malignant progression by imaging and histology
23. Prognostische Information aus präoperativen MR-Daten von Patienten mit Glioblastomen: eine Radiomics-Studie
24. P07.16 Prognostic value of contrast enhancement and histopathological grading in diffuse gliomas depends on IDH1/2 mutation
25. Biological tumour volumes of gliomas in early and standard 20-40 min 18F-FET PET images differ according to IDH mutation status.
26. Detethering of a tethered cord in adult patients - an outcome analysis
27. Stereotactic 125Iodine brachytherapy for the treatment of singular cerebral metastases – Closing the gap?
28. NI-72 * CORRELATION OF VOLUMETRICAL ANALYSES DERIVED FROM 18FET-PET AND MRI WITH OUTCOME IN GLIOBLASTOMA PATIENTS
29. NI-41 * PROGNOSTIC SIGNIFICANCE OF DYNAMIC ANALYSIS OF 18FET-PET IN NEWLY DIAGNOSED HIGH GRADE GLIOMA
30. Brachytherapie zur Behandlung zerebraler Gliome WHO Grad II - Tumorrezidiv oder Tumorrest nach neurochirurgischer Resektion
31. P17.76 * LOW-DOSE RATE STEREOTACTIC IODINE-125 BRACHYTHERAPY FOR THE TREATMENT OF INOPERABLE PRIMARY AND RECURRENT GLIOBLASTOMA: SINGLE-CENTER EXPERIENCE WITH 201 CASES
32. PEDIATRICS CLINICAL RESEARCH
33. Stereotactic brachytherapy of low-grade cerebral glioma after tumor resection
34. Molecular imaging of gliomas with PET: Opportunities and limitations
35. 970 poster RADIOTHERAPY +/− TEMOZOLOMIDE IN ELDERLY PATIENTS WITH GLIOBLASTOMA
36. 147. Diffusion tensor imaging of the corpus callosum distinguishes Parkinson‘s disease from corticobasal syndrome
37. Diffusion Tensor Imaging of the Corpus Callosum distinguishes Parkinson's Disease from Corticobasal Syndrome
38. Stereotactic brachytherapy with iodine-125 seeds for the treatment of inoperable low-grade gliomas in children: long-term outcome.
39. 18 F-FET PET uptake characteristics of long-term IDH-wildtype glioma survivors.
40. Extrahierung von Histogramm- und Textureigenschaften aus parametrischen F-18-FET PET Bildern zur molekulargenetischen und histologischen Klassifizierung von Gliomen.
41. 18 F-FET PET uptake characteristics of long-term IDH-wildtype glioma survivors
42. Correction to: Biological tumour volumes of gliomas in early and standard 20-40 min 18F-FET PET images differ according to <italic>IDH</italic> mutation status.
43. Molekular-genetische und histologische Unterscheidung von Gliomen anhand charakteristischer 18F-FET PET Pharmakokinetik
44. Prognostic value of dynamic 18F-FET PET in oligodendrogliomas
45. 18F-FET PET uptake characteristics of IDH-wildtype, WHO grade II glioma
46. PROGNOSTIC VALUE OF O-(2-[18F]FLUORETHYL)-L-TYROSINE POSITRON EMISSION TOMOGRAPHY (18FET-PET) WITHIN THE CLINICAL COURSE IN NEWLY DIAGNOSED GLIOBLASTOMA.
47. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group.
48. Combination of pre-treatment dynamic [ 18 F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma.
49. Can Radiomics Provide Additional Information in [ 18 F]FET-Negative Gliomas?
50. Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.